Compugen Ltd Receives a Buy from FBR Capital

By Carrie Williams

FBR Capital analyst Vernon Bernardino reiterated a Buy rating on Compugen Ltd (NASDAQ: CGEN) on November 11. The company’s shares opened today at $6.75.

According to TipRanks.com, Bernardino is ranked 0 out of 5 stars with an average return of -19.7% and a 25.6% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as ImmunoCellular Therapeutics, Actinium Pharmaceuticals, and Conatus Pharmaceuticals.

Compugen Ltd has an analyst consensus of Moderate Buy.

Based on Compugen Ltd’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $70K and GAAP net loss of $7.78 million. In comparison, last year the company earned revenue of $229K and had a GAAP net loss of $6.74 million.

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.